Analysts at J.P. Morgan said the outcome of Roche's trial would largely restrict giredestrant's use to the adjuvant setting, a market valued at between $10 billion and $20 billion. "Roche Shares Fall After Breast-Cancer Treatment Misses Goal in Late-Stage Study," at 0936 GMT, incorrectly said the market was valued at between $10 million and $20 million.


(END) Dow Jones Newswires

03-09-26 1144ET